Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
|Slideshows|April 18, 2016
Depression Research Update: April 2016
Author(s)Mark L. Fuerst
The studies discussed in this slideshow assess the benefits of non-traditional therapies for depressive disorders.
Advertisement
References:
1. Falconer CJ, Rovira A, King JA, et al.
2. Macy RJ, Jones E, Graham LM, Roach L.
3. Centre for Addiction and Mental Health.
Advertisement
Related to this article
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Explore PTSD prevalence, comorbidities, and first-line care as we invite clinicians to share cases and research.
Veterans younger than 30 starting antidepressants, and anyone coprescribed opioids and benzodiazepines, will need to sign consent forms starting in 2027.
How genes and early stress interact to shape antisocial behavior, from dopamine and serotonin pathways to MAOA and oxytocin findings.
Policy shifts have opened the door to telehealth buprenorphine for pregnant and postpartum women with OUD, but research, guidelines, and state policy lag behind.
Overlooking how hearing loss and sign language shape the Mental Status Examination can make language deprivation look like psychosis, authors warn.
Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Real-World Data Link LAI Risperidone to Fewer Emergency Visits in Schizophrenia, Improved Bipolar Treatment
2
Nature vs Nurture: The Interplay Between Genetics and Environmental Influences
3
Psychedelics as a Catalyst for Change: The Evolving Competitive Landscape in Depression
4
The Psychiatric Pipeline in Review: Quarter 3, 2026
5